The device was not returned for analysis.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.A conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined; however, the subsequent treatment appears to be related to the operational context of the procedure.The reported patient effects of angina and stenosis are listed in the xience skypoint everolimus eluting coronary stent systems instructions for use as a known patient effects of coronary stenting procedures.There is no indication of a product quality issue with respect to manufacture, design or labeling.Na.
|
It was reported that on (b)(6) 2023, a procedure was performed to treat a lesion in the left anterior descending (lad) coronary artery with no calcification, mild tortuosity and 100% stenosis.The 3.0x28m xience skypoint stent delivery system (sds) was advanced and the stent was implanted successfully.On (b)(6) 2023, the patient developed severe angina and stenosis was confirmed during the angiography.A percutaneous coronary intervention (pci) was performed treat the stenosis and the patient symptoms were resolved.There was no adverse patient sequela.No additional information was provided.
|